Artificial Intelligence
OpGen subsidiary Ares Genetics announces the strategic expansion of ARESdb proprietary contents
- Following successful completion of Phase 1, Ares Genetics has now entered into Phase 2 of its collaboration with a leading U.S. CRO and reference lab, gaining access to 1,000 proprietary clinical isolates from key pathogens
- ARESdb contents has grown by more than 40% in a year
ROCKVILLE, Md., Dec. 14, 2021 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that its subsidiary, Ares Genetics (Ares), has successfully completed Phase 1 of its collaboration with a leading U.S. CRO and reference lab, originally announced in August. During Phase 2, Ares will gain access to 1,000 proprietary genome and AST datasets thereby strategically enriching ARESdb with proprietary data for key pathogens.
Antimicrobial resistance (AMR) is a growing threat to public health believed to be causing 700,000 fatalities globally each year and billions of U.S. dollars in healthcare costs. Fueling the growing threat of AMR is the inappropriate use of ineffective antibiotics, impacting patient outcomes and promoting the emergence and spread of antibiotic resistant pathogens. Leading global health organizations are therefore calling for antibiotic stewardship through diagnostic innovations that promote the optimal use of antibiotic agents.
Conventional culture-based diagnostics can determine effective antibiotics through antibiotic susceptibility testing (AST); however, they tend to be slow and insensitive. Ares Genetics is addressing this problem from a different angle, using artificial intelligence to accurately predict directly from genomic data if a pathogen is susceptible or resistant to a given antibiotic. Central to this approach are the datasets required to train predictive models, comprised of genome and phenotypic AMR data that have been generated under controlled conditions and a robust model training and testing framework.
Ares Genetics has developed ARESdb, a leading database on AMR, and has published several scientific studies on the performance1,2 of its predictive models as well as important considerations of model training3,4. ARESdb not only comprehensively collects known genetic markers for AMR, but also harbors more than 78,000 datasets essential for the development and training of predictive models. This is up by over 40% from around 55,000 datasets a year ago.
“ARESdb is central to our development of AI-powered applications for AMR prediction” stated Dr. Arne Materna, CEO of Ares Genetics. “It is an essential component of a number of our commercial solutions, including sequencing services offered through our service laboratory located in Vienna, Austria, and the recently launched AREScloud web application aimed at infectious disease experts and professionals in infection prevention and control. We are therefore very pleased to see that our efforts to increase access to clinically relevant and proprietary data through strategic collaborations is proving successful.”
The value of ARESdb and machine learning for predicting antibiograms from genomic data is increasingly recognized by key opinion leaders around the world and has recently materialized in a strategic data access transaction under which a global corporation and leader in microbiology and infectious disease diagnostics was granted access to a narrowly defined subset of ARESdb corresponding to 1.1% of the current database contents.
Ares Genetics intends to further increase the value of ARESdb and grow its contents in the coming months and years through strategic collaborations with external partners and by supporting clinical trials conducted by its affiliates at OpGen. OpGen CEO Oliver Schacht added: “Ares will also be applying its next generation sequencing and AI-powered bioinformatics capabilities to analyze the clinical patient samples collected during OpGen’s Unyvero UTI clinical trial in the U.S. which will further expand the unique and proprietary contents of ARESdb. We expect Ares to become one of the key drivers of growth for OpGen in the coming years as we also seek to expand the commercial footprint and activities of Ares in the U.S. beginning in January of 2022.”
References
- Banerjee, R. et al. Core Genome Multi-Locus Sequence Typing and Prediction of Antimicrobial Susceptibility Using Whole Genome Sequences of Escherichia coli Bloodstream Infection Isolates. Antimicrob Agents Ch AAC0113921 (2021) doi:10.1128/aac.01139-21.
- Ferreira, I. et al. Species Identification and Antibiotic Resistance Prediction by Analysis of Whole-Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. J Clin Microbiol 58, (2020).
- Májek, P., Lüftinger, L., Beisken, S., Rattei, T. & Materna, A. Genome-Wide Mutation Scoring for Machine-Learning-Based Antimicrobial Resistance Prediction. Int J Mol Sci 22, 13049 (2021).
- Lüftinger, L., Májek, P., Beisken, S., Rattei, T. & Posch, A. E. Learning From Limited Data: Towards Best Practice Techniques for Antimicrobial Resistance Prediction From Whole Genome Sequencing Data. Front Cell Infect Mi 11, 610348 (2021).
About OpGen, Inc.
OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero®, Acuitas® AMR Gene Panel and the ARES Technology Platform including ARESdb®, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.
For more information, please visit www.opgen.com.
Forward-Looking Statements
This press release includes statements regarding Ares Genetics’ strategic expansion of ARESdb and certain of its related collaboration arrangements. These statements and other statements regarding OpGen’s future plans and goals constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen’s business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
OpGen:
Oliver Schacht
President and CEO
[email protected]
OpGen Press Contact:
Matthew Bretzius
FischTank Marketing and PR
[email protected]
OpGen Investor Contact:
Maxwell Colbert
Edison Group
[email protected]
Artificial Intelligence
APIX and RBI Join Forces to Drive Financial Innovation Through HaRBInger 2024 Hackathon
SINGAPORE, June 21, 2024 /PRNewswire/ — APIX, the leading global collaborative innovation platform for financial institutions and fintechs across over 90 countries, today announced its partnership with the Reserve Bank of India (RBI) to host the prestigious HaRBInger 2024 hackathon. This landmark collaboration aims to bring together the brightest minds from around the world to develop cutting-edge solutions that enhance the security and inclusivity of the financial ecosystem.
Under the overarching themes of Combatting Fraud and Financial Inclusion for the Differently-abled, the hackathon challenges participants to tackle four critical problem statements focused on real-time fraud detection, ensuring transaction anonymity, identifying mule accounts, and empowering the visually impaired in financial transactions.
“At APIX Platform, we are thrilled and proud to once again partner with Reserve Bank of India (RBI) for HaRBInger,” shares Umang Moondra, CEO of APIX. “Reserve Bank of India (RBI) has led from the front in driving innovation in the financial services sector, and HaBRInger 2024’s focus on critical challenges related to fostering security, integrity, transparency, trust and inclusivity in digital transactions, is a testament to the leadership role that they play.”
As a trusted platform utilised by major banks and regulators worldwide, APIX is uniquely positioned to empower innovators and accelerate their journey toward bringing innovative ideas to life. Leveraging innovative technologies such as AI/ML, APIs, Data Analytics, and more, HaRBInger 2024 participants will have the opportunity to create solutions that drive meaningful change and leave a lasting impact on the financial services industry.
The hackathon welcomes individuals, teams, and enterprises from diverse backgrounds and geographies to participate, offering a platform to showcase their skills on a global stage. With exciting prizes up for grabs, including INR 40,00,000 (~USD 48,000) for the winner in each problem statement category and a special prize of INR 20,00,000 (~USD 24,000) for the best all-woman team, the opportunities are substantial.
Registration for HaRBInger 2024 started on June 7, 2024, and will unfold in four exciting phases on the APIX Platform: screening of entries, shortlisting for solution development, solution development with mentoring and support, and the selection of winners.
Don’t miss this opportunity to collaborate with like-minded innovators, gain exposure to industry leaders, and shape the future of finance on the APIX Platform.
For media inquiries or additional details about HaRBInger 2024, please contact [email protected].
For more information and to register now, visit HaRBInger 2024 at: https://hackolosseum.apixplatform.com/h1/harbinger2024
About APIX:
APIX is a collaborative innovation platform for fintechs and innovators across 90+ countries, empowering Financial Institutions to accelerate their innovation journey.
Major banks, insurers, and regulators in the world use APIX to rapidly discover, test, and evaluate solutions by running comprehensive innovation programs, which include innovation challenges and hackathons.
Ideas are everywhere. Bring the best to the table with APIX. Collaborate to innovate today at www.apixplatform.com.
Logo – https://mma.prnewswire.com/media/2443613/4773081/01_LOGO_COLOR_WITH_BLACK__MAIN_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/apix-and-rbi-join-forces-to-drive-financial-innovation-through-harbinger-2024-hackathon-302178678.html
Reinforces Position as a Disruptive Force in Material Science Innovation
PLEASANTON, Calif., June 20, 2024 /PRNewswire/ — Maxterial, a technology company dedicated to pioneering advancements in material science including the commercialization of advanced coatings, has announced the successful closure of its Series A funding round, raising nearly $8 million. This milestone underscores Maxterial’s rising influence in disruptive material science technologies and its commitment to reshaping traditional industry norms with dynamic and environmentally responsible solutions.
Led by CEO Dr. Mehdi Kargar and Chief Technology Officer Dr. Amy Haghdoost, Maxterial has pioneered material science advancements for nearly a decade. The company’s lean approach to reaching the product-growth fit stage has garnered widespread acclaim, attracting a range of customers and influential investors, including Peter Thiel’s Breakout Labs, Pierre Omidyar’s UP2398, and corporate innovation leaders like Saint-Gobain and Anglo American.
The Series A funding round, led by Helios Climate Ventures, with participation from global corporation QEMETICA (formerly Ciech), solidifies Maxterial’s position as a leader in climate-conscious innovation. This capital enables Maxterial to accelerate its R&D efforts, including large-scale trials, expand its products, and scale operations in North America and Europe.
“We are thrilled to have secured nearly $11 million to date in equity financing, which reflects the confidence investors have in our vision, our unique go-to-market strategies, and the transformative potential of our technology,” said Dr. Mehdi Kargar, CEO of Maxterial. “This scalable platform fits many markets in urgent need of dynamic, sustainable solutions. Series A funding enables us to drive transformational growth across multiple industries.”
Maxterial replaces environmentally harmful and energy-inefficient processes using Hexavalent Hard Chrome (H-Chrome) with a superior solution that is safe, environmentally friendly, and cost effective at a time when material science startups have struggled to attract investment. The company breaks those cycles by delivering unique synergies that integrate the needs of investors, customers, supply chains, and industry experts with a product and service model that delivers exceptional performance, accelerates change and mitigates risk.
Maxterial has already gained significant initial traction. Ongoing trials in Europe and North America are attracting early adopters eager for cutting-edge solutions. By prioritizing sustainability, performance, and scalability, Maxterial can protect against wear, heat, and corrosion, reduce carbon footprint, and eliminate toxic materials like hexavalent chromium.
“We set out to create a company that delivers exceptional technology and exceptional returns,” notes Dr. Kargar. “As we accelerate our implementation, we want to share our insights and expertise with fellow entrepreneurs, industry leaders, and investors interested in driving positive change.”
For media inquiries, please contact:
Carmen FerrignoChief Marketing Officer, MaxterialPhone: 215.287.3658Email: [email protected]
About Maxterial:Maxterial is a Bay Area technology company dedicated to pioneering advancements in material science, including the commercialization of advanced coatings. Founded in 2015, Maxterial leverages an eco-systemic lean tech approach to develop innovative solutions that protect against wear, heat, and corrosion while reducing carbon footprint and eliminating toxic materials from industrial processes. Maxterial is committed to driving responsible transformation in the material science industry through thought leadership, innovation, and collaboration that inspires others to embrace responsible innovation.
To learn more, visit Maxterial.com
Logo – https://mma.prnewswire.com/media/2440672/Maxterial__Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/maxterial-raises-nearly-8-million-in-series-a-funding-302177099.html
Artificial Intelligence
Altair Named a Leader in the June 2024 Gartner® Magic Quadrant™ for Data Science and Machine Learning Platforms
Altair recognized in the report’s Leaders’ Quadrant for Completeness of Vision and Ability to Execute
TROY, Mich., June 20, 2024 /PRNewswire/ — Altair (Nasdaq: ALTR), a global leader in computational intelligence, today announced that it has been positioned by Gartner as a Leader in the Magic Quadrant for Data Science and Machine Learning Platforms for its offering, Altair® RapidMiner®. The evaluation was based on specific criteria that analyzed the company’s overall Completeness of Vision and Ability to Execute.
According to the report, “Leaders in this market have a mature, refined, and targeted company and platform strategy that incorporates and leverages generative AI (GenAI) to drive their customers’ business value. They see opportunities for leveraging GenAI that other providers may not see or have made significant investments above and beyond standard offerings. They have the capability to innovate at a speed that outperforms other vendors. In addition, they can clearly articulate how they provide value to the multiple types of personas involved in the process of building data science and machine learning models.”
“We believe being named as a Leader in this latest report validates what we have known for years: Altair has one of the market’s most unique, most comprehensive offerings for data analytics and machine learning,” said James R. Scapa, founder and chief executive officer, Altair. “For us, this placement is also a testament to our unmatched vision, which has defined us since our inception. We are pioneers that define what it means to be at the forefront of technological innovation and computational intelligence. I am incredibly proud of where Altair stands today, and I look forward to the strides we continue to make each day.”
Magic Quadrant reports are a culmination of rigorous, fact-based research in specific markets, providing a wide-angle view of the relative positions of the providers in markets where growth is high and provider differentiation is distinct. Providers are positioned into four quadrants: Leaders, Challengers, Visionaries and Niche Players. The research enables you to get the most from market analysis in alignment with your unique business and technology needs.
View a complimentary copy of the Magic Quadrant report to learn more about Altair’s strengths and cautions, among other provider offerings, at https://web.altair.com/gartner-magic-quadrant-for-data-science-and-machine-learning-platforms-2024.
Gartner Disclaimer
Gartner, Magic Quadrant for Data Science and Machine Learning Platforms, Afraz Jaffri, Aura Popa, Peter Krensky, Jim Hare, Raghvender Bhati, Maryam Hassanlou, Tong Zhang, 17 June 2024.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Altair
Altair is a global leader in computational intelligence that provides software and cloud solutions in simulation, high-performance computing (HPC), data analytics, and AI. Altair enables organizations across all industries to compete more effectively and drive smarter decisions in an increasingly connected world – all while creating a greener, more sustainable future. To learn more, please visit www.altair.com.
Media contacts
Altair Corporate
Altair Investor Relations
Bridget Hagan
Stephen Palmtag
+1.216.769.2658
+1.669.328.9111
[email protected]
[email protected]
Altair Europe/The Middle East/Africa
Charlotte Hartmann
+49 7031 6208 0
[email protected]
Photo – https://mma.prnewswire.com/media/2444041/Altair_Newsroom_NR_Gartner_MQ_Social__2.jpg
Logo – https://mma.prnewswire.com/media/1421069/Altair_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/altair-named-a-leader-in-the-june-2024-gartner-magic-quadrant-for-data-science-and-machine-learning-platforms-302178198.html
-
Artificial Intelligence7 days agoBorderless AI & Cohere team up to build a custom-trained AI model for HR professionals, taking on Deel and Remote.com
-
Artificial Intelligence7 days agoLoRa and LoRaWAN IoT Market worth $32.7 billion by 2029- Exclusive Report by MarketsandMarkets™
-
Uncategorized6 days agoDan’s the man: Why Chinese women are looking to ChatGPT for love
-
Artificial Intelligence7 days agoComplyport’s new AI tool – ViCA.Chat – set to revolutionise compliance support services
-
Uncategorized6 days ago
Meta to use Instagram and Facebook posts from as far back as 2007 to train artificial intelligence tools
-
Artificial Intelligence7 days agoScoring a Seat at UEFA EURO 2024™ with Top-Performing AI-Powered TOSHIBA TV Lineup
-
Uncategorized6 days ago
Picsart teams up with Getty to take on Adobe’s ‘commercially-safe’ AI
-
Uncategorized6 days ago
EU’s new AI rules: Industry opposed to revealing guarded trade secrets
